中国临床解剖学杂志 ›› 2022, Vol. 40 ›› Issue (1): 93-97.doi: 10.13418/j.issn.1001-165x.2022.1.19

• 临床研究 • 上一篇    下一篇

CalliSpheres载药微球子宫动脉栓塞术治疗宫颈癌的疗效评价

高炜, 邹强, 廖军, 邢文阁, 杨雪玲, 倪虹*   

  1. 天津医科大学肿瘤医院介入治疗科,国家肿瘤临床医学研究中心,天津市肿瘤防治重点实验室,
    天津市恶性肿瘤临床医学研究中心,  天津   300060
  • 收稿日期:2020-06-29 出版日期:2022-01-25 发布日期:2022-01-19
  • 通讯作者: 倪虹,教授,主任医师,硕士研究生导师,E-mail:18622221217@163.com
  • 作者简介:高炜(1980-),男,医学博士,副主任医师,从事临床应用断层解剖学与影像学研究、肿瘤介入学临床工作, E-mail: doctorgao99@163.com
  • 基金资助:
    燕山大学亚稳材料制备技术与科学重点实验室开放课题(202101);国家自然科学基金(81100479);河北省自然科学基金(C2021202002);天津市自然科学基金(20JCYBJC00470);2020年度领航精英专项科研基金(XM2020031029501)

Therapeutic evaluation of CalliSpheres drug-loaded microsphere uterine artery embolization in the treatment of cervical cancer

Gao Wei , Zou Qiang,  Liao Jun,  Xing Wenge, Yang Xueling , Ni Hong*   

  1. Department of Interventional Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer Tianjin 300060, China
  • Received:2020-06-29 Online:2022-01-25 Published:2022-01-19

摘要: 目的 评价CalliSpheres载药微球子宫动脉栓塞术治疗局部晚期宫颈癌疗效。  方法 选取2016年2月至2018年9月本介入科收治的宫颈癌患者48例(平均年龄49岁),采用随机数字分配法将患者分为普通微球子宫动脉栓塞+表阿霉素子宫动脉灌注化疗组24例(A组),表阿霉素载药微球子宫动脉栓塞化疗组24例(B组)。每组治疗2个周期,间隔3周。记录出血减少情况,以CT评价肿瘤大小变化,分析骨髓抑制及消化道反应。  结果 (1)两组患者阴道出血均减少;普通微球组术后出血持续时间为(6±1.5)d,载药微球组为(3± 0.8)d,差异有统计学意义,P<0.01。(2)肿瘤缩小率:普通微球组客观缓解率为83.8%,载药微球组为95.8%,差异有统计学意义,P<0.01。(3)副反应:两组患者均出现腹痛,VAS评分普通微球组(8±2)分,载药微球组(3±1)分,差异有统计学意义,P<0.01;骨髓抑制仅发生于普通微球组。  结论 CalliSpheres载药微球治疗宫颈癌较传统的化疗栓塞术具有更高的肿瘤缩小率,术后阴道出血时间更短,无骨髓抑制且腹痛可控。

关键词: 宫颈癌,  化疗栓塞,  栓塞微球,  CalliSpheres微球

Abstract: Objective To evaluate the efficacy of CalliSpheres drug-loaded microsphere uterine artery embolization in the treatment of locally advanced cervical cancer. Methods Forty-eight patients (average age was 49 years old) with cervical cancer admitted to our department from February 2016 to September 2018 were randomly divided into two groups: normal microsphere uterine artery embolization + 24 cases of epirubicin uterine arterial infusion chemotherapy (group A); 24 cases of drug-loaded microspheres (epimycin) uterine artery chemoembolization (group B). Each group was treated with the same procedures three weeks apart, total two times. The reduction in bleeding was recorded, and tumor size changes were evaluated by CT, and bone marrow suppression and digestive tract reactions were analyzed. Results (1) Both groups of patients had reduced vaginal bleeding. The duration of postoperative bleeding in the conventional microsphere group was (6±1.5) days, and that in the drug-loaded microsphere group was (3±0.8) days, the difference was statistically significant (P<0.01). (2) Tumor reduction rate: The objective remission rate of the ordinary microsphere group was 83.8%, and that of the drug-loaded microsphere group was 95.8%. The difference was statistically significant (P<0.01). (3) Abdominal pain occurred in both groups. The VAS score of the general microsphere group was (8±2), and the VAS score of the drug-loaded microsphere group was (3±1). There were statistical difference in the VAS score (P<0.01). Myelosuppression occured only in the normal microsphere group. Conclusions CalliSpheres drug-loaded microspheres have higher tumor shrinkage rate for cervical cancer, shorter postoperative vaginal bleeding, no bone marrow suppression and controllable abdominal pain.

Key words: Cervical cancer,  Chemoembolization,  Embolization microspheres,  CalliSpheres beads

中图分类号: